|
287 Companies |
|
339 Products |
|
339 Products |
|
208 Mechanisms of Action |
|
11 Trials |
|
3331 News |
|
| «12...5657585960616263646566...6869» |
- | sirolimus / Generic mfg.
Trial completion, Adverse events: De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 26, 2012
P2/3, N=70, Completed, Sponsor: University of Alberta
Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial termination, Metastases: Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor (clinicaltrials.gov) - Aug 24, 2012
P1/2, N=5, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Terminated
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment change, Metastases: Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor (clinicaltrials.gov) - Aug 24, 2012
P1/2, N=5, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated N=106 --> 5
- ||||| brivanib alaninate (BMS-582664) / BMS
Trial initiation date, Metastases: BRISK FL: First Line Hepato Cellular Carcinoma (HCC) (clinicaltrials.gov) - Aug 20, 2012
P3, N=1714, Completed, Sponsor: Bristol-Myers Squibb
N=106 --> 5 Initiation date: Dec 1912 --> May 2009
- Halaven (eribulin mesylate) / Eisai
Enrollment closed: Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer (clinicaltrials.gov) - Aug 20, 2012
P2, N=74, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Dec 1912 --> May 2009 Completed --> Active, not recruiting
- | cisplatin / Generic mfg., etoposide IV / Generic mfg.
New P2 trial: First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer (clinicaltrials.gov) - Aug 16, 2012
P2, N=200, Recruiting, Sponsor: Shanghai Gynecologic Oncology Group
- octreotide implant (VP-003) / Endo
Trial termination: Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome (clinicaltrials.gov) - Aug 15, 2012
P1/2, N=10, Terminated, Sponsor: Endo Pharmaceuticals
Completed --> Active, not recruiting Active, not recruiting --> Terminated; Program was terminated for business reasons
- | pimasertib (AS703026) / Day One Biopharma
New P1 trial, Monotherapy: EMR 200066-010: A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy (clinicaltrials.gov) - Aug 15, 2012
P1, N=48, Recruiting, Sponsor: Merck KGaA
- | ganetespib (ADX-1612) / Aldeyra
New P1 trial, Metastases: STA-9090 in Patients With Advanced Hepatocellular Cancer (clinicaltrials.gov) - Aug 14, 2012
P1, N=16, Completed, Sponsor: Massachusetts General Hospital
- dasatinib / Generic mfg.
Enrollment closed, Metastases: Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors (clinicaltrials.gov) - Aug 14, 2012
P2, N=65, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Program was terminated for business reasons Recruiting --> Active, not recruiting
- | Trial suspension, Metastases: Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction (clinicaltrials.gov) - Aug 13, 2012
P2, N=96, Suspended, Sponsor: North Central Cancer Treatment Group
Recruiting --> Active, not recruiting Recruiting --> Suspended
- Lartruvo (olaratumab) / Eli Lilly, Cyramza (ramucirumab) / Eli Lilly
Enrollment closed: Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Aug 12, 2012
P2, N=80, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Suspended Recruiting --> Active, not recruiting
- cisplatin / Generic mfg., gemcitabine / Generic mfg.
New P2 trial: Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) (clinicaltrials.gov) - Aug 9, 2012
P2, N=1, Terminated, Sponsor: University of Michigan Cancer Center
- oxaliplatin / Generic mfg., gemcitabine / Generic mfg.
Trial withdrawal, Metastases: GemOx-PDT: Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma (clinicaltrials.gov) - Aug 8, 2012
P2, N=0, Withdrawn, Sponsor: Technische Universit
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- oxaliplatin / Generic mfg., gemcitabine / Generic mfg.
Enrollment change, Metastases: GemOx-PDT: Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma (clinicaltrials.gov) - Aug 8, 2012
P2, N=0, Withdrawn, Sponsor: Technische Universit
Not yet recruiting --> Withdrawn N=24 --> 0
- || sorafenib / Generic mfg.
Enrollment change: Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=1200, Active, not recruiting, Sponsor: Bayer
N=24 --> 0 N=3000 --> 1200
- Trial completion: A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 7, 2012
P2, N=50, Completed, Sponsor: Gynecologic Oncology Group
N=3000 --> 1200 Suspended --> Completed
- |||| emricasan (IDN 6556) / Amerimmune
Trial completion: Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation (clinicaltrials.gov) - Aug 7, 2012
P2, N=99, Completed, Sponsor: Conatus Pharmaceuticals Inc.
Suspended --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer (clinicaltrials.gov) - Aug 5, 2012
P2, N=6, Terminated, Sponsor: University of Kansas
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Study was stopped due to termination of funding
- | MK-2206 / Merck (MSD), Koselugo (selumetinib) / Merck (MSD), AstraZeneca
New P2 trial: SWOG-S1115: Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy (clinicaltrials.gov) - Aug 5, 2012
P2, N=133, Recruiting, Sponsor: National Cancer Institute (NCI)
- Intron A (interferon ?-2b) / Merck (MSD), Biogen
New P2 trial, Metastases: 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer (clinicaltrials.gov) - Aug 5, 2012
P2, N=14, Active, not recruiting, Sponsor: Western Regional Medical Center
- | dactolisib (RTB101) / Adicet Bio
New P2 trial: BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. (clinicaltrials.gov) - Aug 5, 2012
P2, N=31, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- MK-2206 / Merck (MSD)
Trial initiation date, Metastases: Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma (clinicaltrials.gov) - Aug 2, 2012
P2, N=15, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Study was stopped due to termination of funding Initiation date: Oct 2011 --> Aug 2012
- Dotarem (gadoterate meglumine) / Guerbet
Clinical: Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer (clinicaltrials.gov) - Aug 2, 2012
P=N/A, N=200, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- Enrollment open: PRIGA: Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis (clinicaltrials.gov) - Jul 30, 2012
P4, N=70, Recruiting, Sponsor: Sara Varea
Initiation date: Oct 2011 --> Aug 2012 Not yet recruiting --> Recruiting
- carboplatin / Generic mfg., gemcitabine / Generic mfg.
New P1 trial, Surgery: Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer (clinicaltrials.gov) - Jul 26, 2012
P1, N=20, Recruiting, Sponsor: Case Comprehensive Cancer Center
- |||||||||| Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) / Merck (MSD)
New P3 trial: Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) (clinicaltrials.gov) - Jul 25, 2012
P3, N=2500, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- glycosylated recombinant human interleukin-7 (CYT107) / Revimmune
Trial termination, Metastases: Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer (clinicaltrials.gov) - Jul 24, 2012
P1, N=9, Terminated, Sponsor: Cytheris SA
Not yet recruiting --> Recruiting Recruiting --> Terminated
- Clinical: SEXUTOX: Toxicities of Cervix and Corpus Uteri Carcinomas Treatment and Evaluation of Impact on Sexual Function (clinicaltrials.gov) - Jul 24, 2012
P=N/A, N=180, Recruiting, Sponsor: Centre Oscar Lambret
- Enrollment open, Metastases: Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy (clinicaltrials.gov) - Jul 24, 2012
P2, N=162, Recruiting, Sponsor: Yonsei University
Recruiting --> Terminated Not yet recruiting --> Recruiting
- ubidecarenone topical (BPM 31510) / BPGbio
Trial withdrawal: Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 23, 2012
P2, N=0, Withdrawn, Sponsor: Berg, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- ubidecarenone topical (BPM 31510) / BPGbio
Enrollment change: Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 23, 2012
P2, N=0, Withdrawn, Sponsor: Berg, LLC
Not yet recruiting --> Withdrawn N=160 --> 0
- |||| Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion, Metastases: BIBW 2992 (Afatinib) in Head & Neck Cancer (clinicaltrials.gov) - Jul 23, 2012
P2, N=124, Completed, Sponsor: Boehringer Ingelheim
N=160 --> 0 Active, not recruiting --> Completed
- Surgery: Long-term Outcomes of Total Thyroidectomy Versus Less Than Total Thyroidectomy for Papillary Thyroid Microcarcinoma (clinicaltrials.gov) - Jul 22, 2012
P=N/A, N=2014, Completed, Sponsor: Korean Association of Endocrine Surgeons
- | New P2 trial, Metastases: Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy (clinicaltrials.gov) - Jul 22, 2012
P2, N=162, Recruiting, Sponsor: Yonsei University
- |||| AGS PSCA / Astellas
Trial completion, Combination therapy, Metastases: A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jul 22, 2012
P2, N=205, Completed, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed Active, not recruiting --> Completed
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment change: A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma (clinicaltrials.gov) - Jul 19, 2012
P1, N=75, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed N=45 --> 75
- ||| vorsetuzumab mafodotin (SGN-75) / Pfizer
Trial completion, Metastases: A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma (clinicaltrials.gov) - Jul 19, 2012
P1, N=58, Completed, Sponsor: Seattle Genetics, Inc.
N=45 --> 75 Active, not recruiting --> Completed
- Oncaspar liquid (pegaspargase) / Servier
Trial completion: Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer (clinicaltrials.gov) - Jul 18, 2012
P2, N=4, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P2 trial: Hypofractionated Proton Beam Radiotherapy for Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 16, 2012
P2, N=135, Recruiting, Sponsor: National Cancer Center, Korea
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial completion: Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura (clinicaltrials.gov) - Jul 16, 2012
P3, N=256, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Surgery: Boron Neutron Capture Therapy Following Surgery in Treating Patients With Glioblastoma Multiforme Removed During Surgery (clinicaltrials.gov) - Jul 16, 2012
P1, N=36, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Combination therapy, Metastases: CRUK-ABC-02: Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors (clinicaltrials.gov) - Jul 15, 2012
P3, N=324, Completed, Sponsor: University College, London
Active, not recruiting --> Completed Recruiting --> Completed
- 5-fluorouracil / Generic mfg.
Trial termination, Surgery: Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer (clinicaltrials.gov) - Jul 12, 2012
P2, N=0, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Completed Active, not recruiting --> Terminated; low accrual
- Leukine (sargramostim) / Partner Therap, LucaVax (tertomotide) / GemVax & KAEL
Enrollment closed, Metastases: Immunochemoradiotherapy in Patients With Pancreatic Cancer (clinicaltrials.gov) - Jul 12, 2012
P1, N=11, Active, not recruiting, Sponsor: Providence Health & Services
Active, not recruiting --> Terminated; low accrual Recruiting --> Active, not recruiting
- carboplatin / Generic mfg., docetaxel / Generic mfg.
Biomarker, Preclinical, Retrospective data, Trial termination, Journal, Metastases: Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix (clinicaltrials.gov) - Jul 11, 2012
P1/2, N=15, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Active, not recruiting Completed --> Terminated; slow accrual
- carboplatin / Generic mfg., docetaxel / Generic mfg.
Enrollment change, Metastases: Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix (clinicaltrials.gov) - Jul 11, 2012
P1/2, N=15, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Completed --> Terminated; slow accrual N=64 --> 15
- | CIGB-300 / Center for Genetic Engineering and Biotechnology
New P2 trial: Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application (clinicaltrials.gov) - Jul 11, 2012
P2, N=18, Recruiting, Sponsor: Laboratorio Elea S.A.C.I.F. y A.
- Signifor LAR (pasireotide long acting release) / Recordati
New P2 trial: Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 10, 2012
P2, N=30, Recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
- ||| Provenge (sipuleucel-T) / Bausch Health
Enrollment closed, Metastases: Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer (clinicaltrials.gov) - Jul 10, 2012
P2, N=60, Active, not recruiting, Sponsor: Dendreon
N=64 --> 15 Recruiting --> Active, not recruiting